Neovii Pharmaceuticals Appoints Frédéric Prince as New CEO Following Christian Loss's Retirement
Key Insights
Dr. Christian Loss, CEO of Neovii Pharmaceuticals (search) AG, will retire after a distinguished career and be succeeded by Frédéric Prince PhD effective January 1st, 2026.
Prince brings extensive experience from senior roles at Roche's Pharma Research and Early Development, where he served as Head of Strategy and Chief of Staff to the Head of Oncology.
The new CEO previously led gene therapy programs at bluebird bio (now Genetix Biotherapeutics (search)) and held leadership positions at Novartis Oncology across multiple countries.
Neovii Pharmaceuticals (search) AG announced a leadership transition as Dr. Christian Loss steps down from his role as Chief Executive Officer to take retirement, effective January 1st, 2026. The Swiss-based pharmaceutical company has appointed Frédéric Prince PhD as his successor, bringing extensive experience from major pharmaceutical companies including Roche and Novartis.
New Leadership with Deep Industry Experience
Prince joins Neovii from Roche's Pharma Research and Early Development (pRED), where he most recently served as Head of Strategy and Chief of Staff ad interim to the Head of Oncology. Prior to this strategic role, he acted as Project Team Leader in the research and early development department, heading different programs from immunooncology.
The incoming CEO's career spans significant leadership positions across the pharmaceutical and biotechnology sectors. At bluebird bio, later renamed to Genetix Biotherapeutics (search), Prince served as Vice President and Global Program Lead, where he headed the eli-cel gene therapy program. He also served as General Manager for France, overseeing the company's operations in the country.
Before his work in gene therapy, Prince spent over a decade in leadership roles with increasing responsibilities at Novartis Oncology, working across multiple markets including the United States, Switzerland, Italy, and France. His career has encompassed both research and development as well as commercial functions.
Academic Background and Qualifications
Prince earned his PhD in Molecular Genetics and a Master's Degree in Cell Biology from the Biozentrum of the University of Basel, providing him with a strong scientific foundation for his pharmaceutical industry career.
Continuity and Transition
The Board of Directors expressed confidence that Prince will drive Neovii's continued growth and development. Simultaneously, the company acknowledged Dr. Christian Loss's decades of dedicated service and successful leadership, noting his invaluable contributions to the development of Neovii Pharmaceuticals (search).
Loss will maintain his connection to the company as a member of the Board of Directors following his retirement from the CEO position, ensuring continuity during the leadership transition.